BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Equities research analysts at HC Wainwright lowered their Q4 2025 earnings per share (EPS) estimates for shares of BioHarvest Sciences in a research note issued to investors on Monday, May 19th. HC Wainwright analyst A. Dayal now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their prior estimate of $0.01. HC Wainwright has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences' FY2026 earnings at $0.07 EPS, FY2027 earnings at $0.34 EPS, FY2028 earnings at $0.72 EPS and FY2029 earnings at $1.19 EPS.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. The firm had revenue of $7.64 million for the quarter, compared to the consensus estimate of $8.93 million.
Separately, Craig Hallum started coverage on shares of BioHarvest Sciences in a research report on Monday, May 5th. They set a "buy" rating and a $15.00 target price on the stock.
View Our Latest Stock Analysis on BHST
BioHarvest Sciences Stock Performance
BioHarvest Sciences stock opened at $6.49 on Tuesday. BioHarvest Sciences has a 52 week low of $6.39 and a 52 week high of $7.38. The business's 50 day moving average price is $6.13. The company has a market cap of $106.60 million, a PE ratio of -5.20 and a beta of 0.80.
Institutional Investors Weigh In On BioHarvest Sciences
Hedge funds have recently modified their holdings of the stock. TD Waterhouse Canada Inc. bought a new stake in shares of BioHarvest Sciences in the 4th quarter worth approximately $69,000. True North Advisors LLC raised its holdings in BioHarvest Sciences by 7.6% during the 1st quarter. True North Advisors LLC now owns 44,391 shares of the company's stock valued at $275,000 after acquiring an additional 3,120 shares during the period. Finally, Magnus Financial Group LLC raised its holdings in BioHarvest Sciences by 105.0% during the 1st quarter. Magnus Financial Group LLC now owns 71,733 shares of the company's stock valued at $444,000 after acquiring an additional 36,733 shares during the period.
About BioHarvest Sciences
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
